GlassScriptPhysician profile
Amy L Wirts
NPI 1508820861
$2,623.18
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,440 · 2020: $80.40 · 2021: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $437.26 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $374.54 | 2019 | |
| Novo Nordisk INC | $266.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $250.00 | 2019 | |
| Horizon Therapeutics Plc | $205.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $151.37 | 2019 | |
| Amgen INC. | $111.13 | 2019 | |
| Allergan, INC. | $110.99 | 2019 | |
| Pfizer INC. | $110.15 | 2019 | |
| Genzyme Corporation | $102.52 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100.79 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.37 | 2019 | |
| Phadia US INC. | $84.38 | 2019 | |
| Genentech USA, INC. | $75.34 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $53.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wirts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.